Therapeutic effects of selective cyclooxygenase-2 inhibitor PC407 on 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats

World Chinese Journal of Digestology

Volumn 16, Issue 12, 2008, Pages 1287-1293

  Bai, Hui ^a   Zhang, Bang Le ^a   Li, Yu Hua ^a   You, Yu ^b   Guo, Zhen Jun ^a   Sun, Yang ^a   Mei, Qi Bing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

2,4,6 trinitrobenzene sulfonic acid; Cyclooxygenase; Immunohistochemistry; Selective COX 2 inhibitor; Tumor necrosis factor alpha; Ulcerative colitis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENEMA; PC 407; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLON; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOOSE FECES; NONHUMAN; RAT; REGULATORY MECHANISM; SPLEEN; STATISTICAL SIGNIFICANCE; THYMUS; TREATMENT RESPONSE; ULCER; ULCERATIVE COLITIS;

EID: 47549112927     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v16.i12.1287     Document Type: Article

References (30)

1. Goyette P, Labbé C, Trinh TT, Xavier RJ, Rioux JD. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann Med 2007; 39: 177-199
2. Lukas M, Bortlik M, Maratka Z. What is the origin of ulcerative colitis? Still more questions than answers. Postgrad Med J 2006; 82: 620-625
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-1640
4. Murphy SJ, Ullman TA, Abreu MT. Gut microbes in Crohn's disease: getting to know you better? Am J Gastroenterol 2008; 103: 397-398
5. Stadnicki A, Frysz-Naglak D. Non-steroidal anti-inflammatory drugs and intestinal side effects. Wiad Lek 2007; 60: 286-290
6. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002; 9: 1033-1043
7. Lehmann FS, Beglinger C. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective. Curr Top Med Chem 2005; 5: 449-464
8. Chinese source
9. Lu ZH, Xiong XY, Zhang BL, Lin GC, Shi YX, Liu ZG, Meng JR, Zhou YM, Mei QB. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Acta Pharmacol Sin 2005; 26: 1505-1511
10. Hao LL, Mei QB, Zhang BL, Jia M, Li XQ, Zhang F. PC-407 inhibited proliferation and induced apoptosis in human colon cancer SW-1116 cells. Acta Pharmacol Sin 2004; 25: 1509-1514
11. Chinese source
12. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 2007; 23: 365-369
13. Latinne D, Fiasse R. New insights into the cellular immunology of the intestine in relation to the pathophysiology of inflammatory bowel diseases. Acta Gastroenterol Belg 2006; 69: 393-405
14. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115: 297-306
15. Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 2001; 48: 468-472
16. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434
17. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002; 303: 1248-1254
18. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 910-914
19. Cuzzocrea S, Mazzon E, Serraino I, Dugo L, Centorrino T, Ciccolo A, Sautebin L, Caputi AP. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 2001; 431: 91-102
20. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98: 2076-2085
21. Tsubouchi R, Hayashi S, Aoi Y, Nishio H, Terashima S, Kato S, Takeuchi K. Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats. Digestion 2006; 74: 91-100
22. Zamuner SR, Warrier N, Buret AG, MacNaughton WK, Wallace JL. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 2003; 52: 1714-1720
23. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-455
24. Sasaki S, Hirata I, Maemura K, Hamamoto N, Murano M, Toshina K, Katsu K. Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol 2000; 51: 23-28
25. Hatazawa R, Ohno R, Tanigami M, Tanaka A, Takeuchi K. Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. J Pharmacol Exp Ther 2006; 318: 691-699
26. Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006; 8: 499-505
27. Hassan C, Zullo A, De Francesco V, Campo SM, Morini S, Panella C, Ierardi E. Tumor necrosis factor alpha in ulcerative colitis and diverticular disease associated colitis. Endocr Metab Immune Disord Drug Targets 2007; 7: 187-194
28. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007; 7: 35-41
29. Huang ZF, Massey JB, Via DP. Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol 2000; 59: 187-194
30. Ulcar R, Peskar BA, Schuligoi R, Heinemann A, Kessler HH, Santner BI, Amann R. Cyclooxygenase inhibition in human monocytes increases endotoxin-induced TNF alpha without affecting cyclooxygenase-2 expression. Eur J Pharmacol 2004; 501: 9-17